Ibrance growth trends
In 2017, Pfizer’s (PFE) Ibrance, a cyclin-dependent kinase (or CDK4/6) inhibitor, reported revenues of $3.1 billion, which is a YoY (year-over-year) operational growth of 47%. The robust growth is attributable to the drug’s favorable benefit-risk profile, strong clinical data, and first mover advantage the drug enjoyed in this class of drugs.
Additionally, the positive experience of physicians and patients has also helped boost the adoption of the drug around the world, mainly in the metastatic breast cancer setting. At the end of 2017, Ibrance managed to secure regulatory approval in about 80 countries globally, while the drug was being prescribed to more than 100,000 patients.
Ibrance, however, had a one-time price adjustment in certain developed European markets. Pfizer has entered into certain agreements in these countries to bring down the price of Ibrance and make it comparable to the prices of some historical European oncology analogues. That, however, is considered a major positive trend for the drug since it’s expected to significantly broaden patient access in these markets.
The above diagram shows the growth trajectory for Pfizer’s oncology portfolio.
Despite the launch of other CDK4/6 inhibitors such as Eli Lilly’s (LLY) Verzenio and Novartis’s (NVS) Kisqali in the HR-positive, HER2-negative breast cancer indication, Ibrance has managed to maintain its market-leading position in this class of drugs. It’s currently covered by 98% of commercial healthcare plans and all Medicare Part D plans in the United States.
Pfizer estimates that around 60% of the newly diagnosed HER2-positive or HER2-negative/HR-positive breast cancer patients are using CDK4/6 inhibitor therapies. Only half of these breast cancer patients are currently using CDK4/6 inhibitors across all lines of treatment. So the availability of more drugs is expected to increase penetration of this class of drugs. Ibrance is expected to continue to be a market leader in the coming years. To know more about Ibrance’s growth trends in 2017, please refer to Ibrance: Major Growth Driver for Pfizer in 2017
In the next part of this series, let’s take a look at the label expansion programs for Ibrance and Xtandi.